Ali Soleymannezhad net worth and biography

Ali Soleymannezhad Biography and Net Worth

Insider of MaxCyte

Mr. Soleymannezhad brings 20 years of technical sales, strategic marketing, and bioprocessing and bioanalysis product management and development to his role at MaxCyte. Recently, as an Executive Vice President for the Separations and Purification Business at Tosoh Bioscience, he led a 140-member global team across four sites. During his tenure at Tosoh, Mr. Soleymannezhad was also Vice President of Global Marketing and Business Development, Director of Sales and Marketing – Americas, and served on the boards of Tosoh Bioscience, LLC, and Semba Biosciences. Mr. Soleymannezhad holds a Master of Business Administration from Rice University's Jones Graduate School of Business as well as master's and bachelor's degrees in chemical and biochemical engineering from the University of Western Ontario.

What is Ali Soleymannezhad's net worth?: The estimated net worth of Ali Soleymannezhad is at least $93.91 thousand as of March 18th, 2025. Mr. Soleymannezhad owns 59,439 shares of MaxCyte stock worth more than $93,914 as of December 5th. This net worth estimate does not reflect any other investments that Mr. Soleymannezhad may own. Learn More about Ali Soleymannezhad's net worth.
How do I contact Ali Soleymannezhad?: The corporate mailing address for Mr. Soleymannezhad and other MaxCyte executives is 22 FIRSTFIELD ROAD SUITE 110, GAITHERSBURG MD, 20878. MaxCyte can also be reached via phone at 301-944-1700 and via email at [email protected]. Learn More on Ali Soleymannezhad's contact information.
Has Ali Soleymannezhad been buying or selling shares of MaxCyte?: Ali Soleymannezhad has not been actively trading shares of MaxCyte over the course of the past ninety days. Most recently, Ali Soleymannezhad sold 1,211 shares of the business's stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $3.18, for a transaction totalling $3,850.98. Following the completion of the sale, the insider now directly owns 59,439 shares of the company's stock, valued at $189,016.02. Learn More on Ali Soleymannezhad's trading history.
Who are MaxCyte's active insiders?: MaxCyte's insider roster includes Douglas Doerfler (Founder), Douglas Doerfler (Founder), Stanley Erck (Director), John Johnston (Director), Maher Masoud (CEO), David Sandoval (Senior Vice President and General Counsel), Ali Soleymannezhad (Insider), and Douglas Swirsky (CFO). Learn More on MaxCyte's active insiders.
Are insiders buying or selling shares of MaxCyte?: In the last year, MaxCyte insiders bought shares 5 times. They purchased a total of 355,000 shares worth more than $479,950.00. In the last year, insiders at the sold shares 7 times. They sold a total of 29,653 shares worth more than $95,594.74. The most recent insider tranaction occured on August, 13th when CFO Douglas J Swirsky bought 50,000 shares worth more than $64,500.00. Insiders at MaxCyte own 3.3% of the company. Learn More about insider trades at MaxCyte.
Information on this page was last updated on 8/13/2025.

Ali Soleymannezhad Insider Trading History at MaxCyte

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/18/2025	Sell	1,211	$3.18	$3,850.98	59,439

Ali Soleymannezhad Buying and Selling Activity at MaxCyte

MaxCyte Company Overview

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Today's Range

Now: $1.58

$1.50

$1.62

50 Day Range

MA: $1.62

$1.44

$1.83

2 Week Range

Now: $1.58

$1.26

$5.20

Volume

577,871 shs

Average Volume

856,912 shs

Market Capitalization

$168.54 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22